Insiders · RARE

RARE insider transactions

Ultragenyx Pharmaceutical Inc. (RARE) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

RARE insiders

Everyone who has filed a Form 3, 4, 5 or 144 at Ultragenyx Pharmaceutical Inc., latest first. Follow anyone to get their next filing.

• Theodore Alan HuizengaSVP, Chief Accounting Officer-$928K
• Karah Herdman ParschauerEVP and Chief Legal Officer-$3.86M
• Howard HornChief Financial Officer, since October 2023-$1.8M
• Sanders Corazon (Corsee) D.Director, since June 2021-$339K
• Matthew K FustDirector-$620K
• Shehnaaz SulimanDirector-$144K
• Amrit RayDirector, since April 2022
• Michael NarachiDirector
• Daniel G WelchDirector
• Deborah DunsireDirector
• Eric CrombezEVP and Chief Medical Officer, since May 2023-$663K
• Emil D KakkisPresident & CEO, Director-$21.2M
• Dennis Karl HuangOfficer-$874K
• John Richard PinionOfficer-$2.39M
• Erik HarrisEVP & Chief Commercial Officer-$2.47M
• Thomas Richard KassbergCbo & EVP-$3.73M
• Mardi DierOfficer-$814K
• Lars EkmanDirector
• Camille L BedrosianOfficer-$5.84M
• William AliskiDirector-$1.12M

Recent Form 3, 4, and 5 filings for RARE

• 20d
  Chief Financial Officer Horn Howard sold $107,898 worth of shares (7,066 units at $15.27) (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 53d
  SVP, Chief Accounting Officer Huizenga Theodore Alan sold $17,410 worth of shares (1,283 units at $13.57), decreasing direct ownership by 2% to 67,863 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 61d
  SVP, Chief Accounting Officer Huizenga Theodore Alan sold $2,252 worth of shares (161 units at $13.99), decreasing direct ownership by 0.23% to 69,146 units (SEC Form 4) to cover taxes

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 96d
  EVP and Chief Legal Officer Parschauer Karah Herdman sold $47,348 worth of shares (1,900 units at $24.92), decreasing direct ownership by 2% to 92,562 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 96d
  Chief Financial Officer Horn Howard sold $117,024 worth of shares (4,696 units at $24.92), decreasing direct ownership by 5% to 96,295 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 125d
  Chief Financial Officer Horn Howard sold $155,645 worth of shares (4,698 units at $33.13), decreasing direct ownership by 4% to 100,991 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 145d
  Director Sanders Corazon (Corsee) D. sold $50,100 worth of shares (2,000 units at $25.05), decreasing direct ownership by 9% to 21,095 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 145d
  EVP and Chief Legal Officer Parschauer Karah Herdman sold $46,753 worth of shares (1,899 units at $24.62), decreasing direct ownership by 2% to 94,462 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 159d
  Chief Financial Officer Horn Howard sold $110,602 worth of shares (4,653 units at $23.77), decreasing direct ownership by 4% to 105,689 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 173d
  Director Fust Matthew K was granted 7,751 shares, increasing direct ownership by 30% to 33,696 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 174d
  Director Suliman Shehnaaz was granted 7,751 shares and sold $144,189 worth of shares (5,740 units at $25.12), increasing direct ownership by 8% to 27,951 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 174d
  Director Ray Amrit was granted 7,751 shares, increasing direct ownership by 33% to 31,116 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 174d
  Director Sanders Corazon (Corsee) D. was granted 7,751 shares, increasing direct ownership by 51% to 23,095 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 174d
  Director Narachi Michael was granted 7,751 shares, increasing direct ownership by 24% to 40,441 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 174d
  Director Welch Daniel G was granted 7,751 shares, increasing direct ownership by 24% to 40,441 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 174d
  Director Dunsire Deborah was granted 7,751 shares, increasing direct ownership by 25% to 38,566 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 186d
  EVP and Chief Medical Officer Crombez Eric sold $8,586 worth of shares (344 units at $24.96), decreasing direct ownership by 0.31% to 111,189 units (SEC Form 4) to cover taxes

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 188d
  Chief Financial Officer Horn Howard sold $116,607 worth of shares (4,683 units at $24.90), decreasing direct ownership by 4% to 110,342 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 198d
  SVP, Chief Accounting Officer Huizenga Theodore Alan was granted 20,241 shares, increasing direct ownership by 42% to 68,911 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 202d
  SEC Form 4 filed by Kakkis Emil D

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 202d
  SEC Form 4 filed by Huang Dennis Karl

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 202d
  SEC Form 4 filed by Pinion John Richard

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 202d
  SEC Form 4 filed by Parschauer Karah Herdman

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 202d
  SEC Form 4 filed by Harris Erik

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 202d
  SEC Form 4 filed by Crombez Eric

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 202d
  SEC Form 4 filed by Horn Howard

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 220d
  SEC Form 4 filed by Horn Howard

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 243d
  SEC Form 4 filed by Ultragenyx Pharmaceutical Inc.

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 249d
  Officer Pinion John Richard was granted 11,137 shares and sold $228,661 worth of shares (10,029 units at $22.80), increasing direct ownership by 1% to 110,026 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 249d
  EVP & Chief Commercial Officer Harris Erik was granted 11,643 shares and sold $240,289 worth of shares (10,539 units at $22.80), increasing direct ownership by 2% to 89,515 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 249d
  President & CEO Kakkis Emil D was granted 71,177 shares and sold $1,240,411 worth of shares (54,404 units at $22.80), increasing direct ownership by 3% to 658,994 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 249d
  EVP and Chief Legal Officer Parschauer Karah Herdman was granted 11,137 shares and sold $185,478 worth of shares (8,135 units at $22.80), increasing direct ownership by 4% to 76,346 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 249d
  SVP, Chief Accounting Officer Huizenga Theodore Alan covered exercise/tax liability with 148 shares and sold $37,210 worth of shares (1,632 units at $22.80), decreasing direct ownership by 4% to 48,670 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 249d
  Chief Financial Officer Horn Howard was granted 6,143 shares and sold $227,538 worth of shares (10,044 units at $22.65), decreasing direct ownership by 4% to 85,034 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 249d
  EVP and Chief Medical Officer Crombez Eric was granted 11,643 shares and sold $160,261 worth of shares (7,029 units at $22.80), increasing direct ownership by 7% to 76,301 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 249d
  Officer Huang Dennis Karl covered exercise/tax liability with 999 shares and was granted 11,137 shares, increasing direct ownership by 9% to 124,729 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 278d
  Chief Financial Officer Horn Howard sold $72,117 worth of shares (3,061 units at $23.56), decreasing direct ownership by 3% to 88,935 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 307d
  Chief Financial Officer Horn Howard sold $71,946 worth of shares (3,150 units at $22.84), decreasing direct ownership by 3% to 91,996 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 313d
  SVP, Chief Accounting Officer Huizenga Theodore Alan sold $2,922 worth of shares (85 units at $34.38), decreasing direct ownership by 0.17% to 50,450 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 332d
  Chief Financial Officer Horn Howard sold $112,087 worth of shares (3,081 units at $36.38), decreasing direct ownership by 3% to 95,146 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 390d
  Chief Financial Officer Horn Howard sold $250,252 worth of shares (7,942 units at $31.51), decreasing direct ownership by 7% to 98,227 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 415d
  SVP, Chief Accounting Officer Huizenga Theodore Alan sold $1,867 worth of shares (64 units at $29.17), decreasing direct ownership by 0.13% to 50,242 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 422d
  EVP and Chief Legal Officer Parschauer Karah Herdman sold $76,366 worth of shares (2,450 units at $31.17), decreasing direct ownership by 3% to 73,271 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 426d
  SVP, Chief Accounting Officer Huizenga Theodore Alan sold $2,637 worth of shares (84 units at $31.39), decreasing direct ownership by 0.17% to 50,306 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 503d
  Director Sanders Corazon (Corsee) D. sold $89,923 worth of shares (2,405 units at $37.39), decreasing direct ownership by 14% to 15,344 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 538d
  Director Suliman Shehnaaz was granted 5,740 shares, increasing direct ownership by 28% to 25,940 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 538d
  Director Welch Daniel G was granted 5,740 shares, increasing direct ownership by 21% to 32,690 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 538d
  Director Sanders Corazon (Corsee) D. was granted 5,740 shares, increasing direct ownership by 48% to 17,749 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 538d
  Director Narachi Michael was granted 5,740 shares, increasing direct ownership by 21% to 32,690 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 538d
  Director Fust Matthew K was granted 5,740 shares, increasing direct ownership by 28% to 25,945 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 538d
  Director Dunsire Deborah was granted 5,740 shares, increasing direct ownership by 23% to 30,815 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 538d
  Director Ray Amrit was granted 5,740 shares, increasing direct ownership by 33% to 23,365 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 551d
  EVP and Chief Medical Officer Crombez Eric sold $28,901 worth of shares (762 units at $37.93), decreasing direct ownership by 0.55% to 71,530 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 608d
  Chief Financial Officer Horn Howard sold $72,114 worth of shares (1,785 units at $40.40), decreasing direct ownership by 2% to 106,169 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 613d
  CBO & EVP Kassberg Thomas Richard was granted 18,443 shares, sold $253,779 worth of shares (6,028 units at $42.10) and covered exercise/tax liability with 508 shares, increasing direct ownership by 5% to 264,730 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 613d
  EVP and Chief Legal Officer Parschauer Karah Herdman was granted 18,443 shares and sold $540,817 worth of shares (12,846 units at $42.10), increasing direct ownership by 8% to 75,287 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 613d
  EVP and Chief Medical Officer Crombez Eric was granted 31,784 shares and sold $376,584 worth of shares (8,945 units at $42.10), increasing direct ownership by 49% to 71,922 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 613d
  Officer Pinion John Richard was granted 32,937 shares, sold $607,882 worth of shares (14,439 units at $42.10) and covered exercise/tax liability with 31 shares, increasing direct ownership by 21% to 108,428 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 613d
  President & CEO Kakkis Emil D was granted 150,560 shares and sold $4,153,571 worth of shares (98,434 units at $42.20), increasing direct ownership by 14% to 641,731 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
• 613d
  EVP & Chief Commercial Officer Harris Erik was granted 35,256 shares and sold $635,836 worth of shares (15,103 units at $42.10), increasing direct ownership by 31% to 87,855 units (SEC Form 4)

  4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)